Webcast

SHARE

Leveraging Clinical Trials to Improve Health and Cut Costs in Oncology

Date: Thursday, July 11, 2024

Time: 2 pm ET | 11 am PT

Cost: Complimentary

Sponsored by:

Cancer care is evolving rapidly, from the advent of molecular diagnostic tools guiding personalized treatments to novel therapies, and better outcomes are possible. Clinical trials can be a critical entry point for members to access some of these cutting-edge treatments and interventions before they become FDA approved. Benefits leaders who understand the impact of clinical trials in oncology can offer new ways to control costs and improve outcomes for plan members.

In this webcast, we'll demystify clinical trials and explain how benefits advisors and employers can benefit from understanding their potential impact on health outcomes and costs.

Join this webcast to discover the benefits and risks of clinical trials. You'll learn:

  • The complexities of navigating clinical trials on behalf of members and what it takes to successfully enroll and clinically benefit
  • Obstacles members face in accessing clinical trials, and how to overcome them
  • What advisors and benefit leaders should look for in care navigation partners

Register Now!

Speaker(s)

Natalya Gertsik, PhD | Vice President, ClearCancer Solution | PHM

Dr. Gertsik is an accomplished healthcare professional with expertise in population health risk management, healthcare services, workforce health, & biopharmaceuticals. At PHM, Natalya leads our ClearCancer™ Solution to support organizations in providing the best of what's possible in cancer care to their members. Natalya advises employers on emerging and chronic health risks, providing actionable guidance to optimize cancer care at both the organizational and individual level. This includes improving cancer outcomes and reducing wasteful medical spend, benefits and formulary design, precision medicine adoption, case management approaches, and the use of the latest early detection technologies.

Natalya received her Bachelor of Arts in Biochemistry from New York University and her Doctorate in Biochemistry from Weill Cornell Graduate School of Medical Sciences. Her PhD work focused on Alzheimer's disease drug development and helped illuminate the reasons behind a high-profile Alzheimer's disease drug failure in late-stage clinical trials. Her findings were published in the journal of Cell Chemical Biology.

Having issues seeing the form? Click here!

Questions? Please email [email protected] or call at (212) 457-4981